LIQUIDIA TECHNOLOGIES INC

NASDAQ: LQDA (Liquidia Corporation)

Last update: 14 Nov, 5:33AM

57.41

-0.71 (-1.22%)

Previous Close 58.12
Volume 1,870,344
Price / Earnings (Forward) 14.36
Price / Sales 8.26
Price / Book 21.86
52 Weeks Range
22.31 (-61%) — 93.61 (63%)
Operating Margin (TTM) -1,135.42%
Diluted EPS (TTM) -1.71
Quarterly Revenue Growth (YOY) 5.00%
Total Debt/Equity (MRQ) 297.04%
Current Ratio (MRQ) 2.93
Operating Cash Flow (TTM) -99.23 M
Levered Free Cash Flow (TTM) -64.38 M
Return on Assets (TTM) -37.66%
Return on Equity (TTM) -203.98%

AIStockmoo Score

-1.3
High debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on up days. A recent move above resistance has not been confirmed. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Institutions net +0.70% of shares in their latest 13F filings: 192 holders increased, 180 decreased (quarter to 30 Sep 2026). info
Short interest +47.7% from 31 Aug to 30 Oct 2026, 5.3 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector outperforming the market.
The pillars agree, so the score is strengthened.
Earnings per share have mostly fallen. Made a loss in recent years. info
Below its medium-term trend line. info
Price is near its 52-week average. Up over 5 years. info
Short-term momentum rising. info
Price is between support and resistance. Levels trending up. info
Final Score -1.28
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Liquidia Corporation Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
LQDA - - - 21.86 -1.3
KNSA 7 B - 71.95 10.51 1.9
AMLX 3 B - - 4.70 0.0
ETON 2 B - 39.51 20.56 1.7
CABR 8 M - - - -1.6
GELS 3 M - - 0.300 -2.7

Select this tab to load the latest available analysis.

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 13.64%
% Held by Institutions 65.04%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 87.04%

Positions Holders Shares
Increased 192 8,915,003
Decreased 180 7,332,603
New 69 1,950,948
Sold out 85 2,906,369

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 17,511,349 5.3
15 Oct 2026 17,303,701 2.0
30 Sep 2026 12,640,721 3.8
15 Sep 2026 12,377,976 11.4
31 Aug 2026 11,858,334 10.2
14 Aug 2026 11,856,100 6.5

FINRA short interest via Nasdaq, reported twice a month.

6 Positive 2 Negative 2 Neutral
Date Type Details
11 Nov 2026 Yahoo Finance LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.
11 Nov 2026 Yahoo Finance LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.
11 Nov 2026 Yahoo Finance 3 Insider Selling Stories; 3 Different Signals for Investors
Insiders at Liquidia, Brinker International and Procter & Gamble have been selling shares, but context like analyst targets, institutional ownership and earnings trends shows the signals differ by company.
10 Nov 2026 Yahoo Finance Liquidia (LQDA) Q3 2026 Earnings Call Transcript
Record October shipments and a widening prescriber base followed a costly settlement.
10 Nov 2026 Yahoo Finance Liquidia Q3 Earnings Call Highlights
Liquidia (NASDAQ:LQDA) reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics. YUTREPIA net product sales rose to $22…
10 Nov 2026 Yahoo Finance Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the…
10 Nov 2026 Yahoo Finance Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +3.90% and +20.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
10 Nov 2026 Yahoo Finance Liquidia Corporation Reports Third Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026October 2026 total patient shipments reached their highest monthly level since launchResolved all litigation with United Therapeutics through a global…
09 Nov 2026 Yahoo Finance Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power
Liquidia has delivered a very strong share price run in recent years, and with the stock last closing at US$47.87 the key question is whether that price can be explained by the company’s earnings power. After such a move, you need to ask if the story in the income statement keeps up with the story…
03 Nov 2026 Yahoo Finance Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026…
30 Oct 2026 Yahoo Finance Why Did Insmed Stock Jump?
For questions about this article or underlying research, email [email protected].
29 Oct 2026 Yahoo Finance Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
29 Oct 2026 Yahoo Finance What Is Behind Liquidia's Lead Over Its Industry?
For questions about this article or underlying research, email [email protected].
28 Oct 2026 Yahoo Finance Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Show more

Recent Signals candle patterns and EMA crosses

▼ Death cross 18 sessions ago · 20 Oct
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on up days. A recent move above resistance has not been confirmed.
Nearest support: 55.04 – 57.00 · weak level
Nearest resistance: 58.18 – 60.73 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria